中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态尚未招聘
赞助商
Shanghai Mental Health Center

关键词

抽象

This project is mainly to clarify the optimal treatment plan and the treatment recommendation sequence of different drugs in Chinese first-episode schizophrenia patients,to identify the optimized sequential treatment regimen for the treatment of resistance patients and provide new evidence for the revision of the guidelines for the treatment of schizophrenia.

描述

This project will be a large sample, multi-center clinical trials for first episode schizophrenia. We plan to get a clear initial regimen and the drug recommendation in the treatment of first episode schizophrenia in China, based on the efficacy, adverse effect and pharmacoeconomics evaluation for the most widely used antipsychotic drugs (amisulpride, risperidone, olanzapine, aripiprazole ) and paliperidone injection. We will carry out sequential treatment trials in first-episode treatment resistant patients (Phase 2: Randomized controlled trials of other antipsychotic drugs that are not used in Phase 1 and paliperidone injection; Phase 3: Clozapine monotherapy, oral administration of other drugs or long-acting injection in treatment; Phase 4: Clozapine combination therapy or any combination of two other antipsychotics), so that we could get a better sequential treatment protocol based on the therapeutic outcome. The current project has great clinical significance.

日期

最后验证: 01/31/2018
首次提交: 02/11/2018
提交的预估入学人数: 04/16/2018
首次发布: 04/26/2018
上次提交的更新: 07/29/2018
最近更新发布: 07/31/2018
实际学习开始日期: 09/30/2018
预计主要完成日期: 08/31/2020
预计完成日期: 08/31/2021

状况或疾病

Schizophrenia

干预/治疗

Drug: Olanzapine

Drug: Risperidone

Drug: Amisulpride

Drug: Aripiprazole

Drug: Paliperidone long-acting injection

相 4

手臂组

干预/治疗
Experimental: Olanzapine
dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
Drug: Olanzapine
Commonly used oral antipsychotics intervention therapy.
Experimental: Risperidone
dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
Drug: Risperidone
Commonly used oral antipsychotics intervention therapy.
Experimental: Amisulpride
dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
Drug: Amisulpride
Commonly used oral antipsychotics intervention therapy.
Experimental: Aripiprazole
dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
Drug: Aripiprazole
Commonly used oral antipsychotics intervention therapy.
Experimental: Paliperidone long-acting injection
dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
Drug: Paliperidone long-acting injection
long-acting injection

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- Meet the diagnostic criteria of Diagnostic and Statistical Manual Diploma in Social Medicine(DSM-V) schizophrenia or schizophreniform psychosis

- Patient interview using the MINI-International Neuropsychiatric Interview(MINI 7.0)

- 18 to 40 years of age

- First episode, disease course less than 3 years

- Antipsychotic naïve, or the time of taking the same type of antipsychotic <2 weeks (2 weeks is a time criterion to determine the efficacy in lots of studies), and cumulative antipsychotic drug exposure time <6 weeks Informed consent.

In addition, the severity of psychiatric symptoms is moderate or above, the specific criteria are:

- All patients have a score ≥4 on at least one Positive and Negative Syndrome Scale (PANSS; 17) psychosis item (delusions, conceptual disorganization, hallucinatory behavior, grandiosity, or suspiciousness/persecution)

- All patients have a score ≥4 (moderately ill) on the severity item of the Clinical Global Impression scale (CGI; 19) at the point of maximum severity of illness to date

Exclusion Criteria:

- organic disease

- severe physical illness

- psychoactive substance dependence

- mental retardation

- pregnancy or breast-feeding patients

- extreme agitation, stupor, negative suicide

- other non-cooperation or risk patients

结果

主要结果指标

1. Change from baseline in Positive and Negative Syndrome Scale [PANSS] [baseline,2 months,4 months and 6 months and 12 months]

Reduction to the PANSS total score≥50%

次要成果指标

1. Change from baseline in Psychiatric Symptom severity scale (CRDPSS) [baseline,2 months,4 months and 6 months and 12 months]

Psychiatric Symptom severity scale (CRDPSS)

2. Change from baseline in the Cost inventory [baseline,2 months,4 months and 6 months and 12 months]

Cost inventory

3. Change from baseline in overall clinical impression Scale (CGI) [baseline,2 months,4 months and 6 months and 12 months]

overall clinical impression Scale (CGI)

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge